Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-daratumumab
- Development stage
- Preclinical
- Lead developer
- University of Wisconsin
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
177Lu-daratumumab is a radiopharmaceutical agent composed of the human monoclonal antibody daratumumab labeled with the beta-emitting radioisotope lutetium-177 (177Lu). Daratumumab specifically targets CD38, a transmembrane glycoprotein overexpressed in multiple myeloma and various types of lymphoma. By binding to CD38-positive cells, the compound delivers localized ionizing radiation from the 177Lu isotope, which has a half-life of approximately 6.7 days and a tissue penetration range of about 2 mm. This targeted approach, known as radioimmunotherapy (RIT), aims to induce tumor cell death while minimizing damage to surrounding healthy tissue. The gamma emissions of 177Lu also allow for theranostic applications, enabling non-invasive imaging and dosimetry. It is currently being investigated in preclinical models for hematological malignancies.
- Other names
- 177Lu-DTPA-daratumumab177Lu-DOTA-daratumumablutetium (177Lu) daratumumab
02
Targets
CD38 (Cluster of Differentiation 38)
Beyond the preview
Go deeper on 177Lu-daratumumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177Lu-daratumumab.